Teva Pharmaceuticals and Biolojic Design are collaborating on developing BD9, a novel therapy targeting TH2-driven inflammatory diseases like atopic dermatitis and asthma. The initiation of IND-enabling studies signifies a crucial step towards potential clinical trials and addressing unmet patient needs.